Drug patent law reform and shortages

Myronuk, Lonn D.S.; Meagher, Joseph B.A.
November 1993
CMAJ: Canadian Medical Association Journal;11/1/1993, Vol. 149 Issue 9, p1225
Academic Journal
No abstract available.


Related Articles

  • Big pharma in South Africa launches IP campaign.  // PharmacoEconomics & Outcomes News;Feb2014, Vol. 696 Issue 1, p1 

    The article reports on protests from pharmaceutical companies against draft patent law reforms in South Africa which would prevent pharmaceutical companies from tweaking formulations of its drugs to extend patents, according to the journal "Lancet."

  • Companies clue in to patent law reform. Oczek, Jeremy // Buffalo Law Journal;3/12/2012, Vol. 84 Issue 21, p3 

    A discussion related to patent law reform of the America Invents Act of 2011, is presented.

  • Eshoo defends bio-drugs law. Lillis, Mike // Hill;7/22/2010, Vol. 17 Issue 86, p16 

    The article reports on the healthcare reform law of U.S. Representative Anna Eshoo that safety precautions for biosimilars when patents expire on the breakthrough of drugs are better left in the hands of federal regulators than the pharmaceutical companies.

  • Pharmaceutical intellectual property laws need reform.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p335 

    The article reports on the need to reform the intellectual property law of the pharmaceutical industry in the U.S. It notes that the reform aims to encourage and protect innovation in developing new drugs. It adds that the regulations make the adjudication of patent validity an extraordinarily...

  • Ghost of the Past: Does the USPTO's Scientific and Technical Background Requirements Still Make Sense? Blake, Corey B. // Texas Law Review;Feb2004, Vol. 82 Issue 3, p735 

    Discusses a proposal to broaden or eliminate technical background requirement for patent prosecutors in the U.S. Background on the patent law; Ways to reform the technical background requirement; Effects of the reform on patent cost, quality and members of the patent bar.

  • PONDERING PATENTS: FIRST PRINCIPLES AND FRESH POSSIBILITIES. Vetter, Greg R. // Houston Law Review;Symposium 2012, Vol. 50 Issue 2, p319 

    An introduction is presented in which the author discusses various reports within the issue on topics including software patent reform, patent litigation and change in patent law.

  • Funding and performance at the US Patent and Trademark Office. Hegde, Deepak // Nature Biotechnology;Feb2012, Vol. 30 Issue 2, p148 

    Despite recent patent law reforms, the US Patent and Trademark Office's ability to deal with inefficiencies in patent examination will continue to rely on the annual Congressional appropriations process.

  • No shortage of blame. Lee, Jaimy // Modern Healthcare;7/30/2012, Vol. 42 Issue 31, p8 

    The article discusses a report released by the United States House of Representatives' Committee on Oversight and Government Reform in 2012 regarding the record number of drugs in short supply. Topics include how increased drug law enforcements by the U.S. Food and Drug Administration (FDA) have...

  • Drug industry confounds analysts' forecasts.  // Life Science Today;Jun2000, Vol. 1 Issue 3, p4 

    Focuses on the increased first quarter sales in drug industry in Europe. Percentage of the growth of sales; Impact of patent expiries on health reform; Advantage of patent protection of drugs.

  • Biomedical patents: Overturning preconceptions.  // Nature Medicine;Nov2009, Vol. 15 Issue 11, p1239 

    The article focuses on the debate of lawyers and doctors over biomedical patents. It states that need for legal changes including the reduction of infringement litigation on patents and fast marketing of generic drugs are being explored by the regulators in Europe. Moreover, it notes that Patent...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics